1. Home
  2. APRE vs YHC Comparison

APRE vs YHC Comparison

Compare APRE & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • YHC
  • Stock Information
  • Founded
  • APRE 2006
  • YHC 2021
  • Country
  • APRE United States
  • YHC United States
  • Employees
  • APRE N/A
  • YHC N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • YHC Beverages (Production/Distribution)
  • Sector
  • APRE Health Care
  • YHC Consumer Staples
  • Exchange
  • APRE Nasdaq
  • YHC Nasdaq
  • Market Cap
  • APRE 8.3M
  • YHC 8.3M
  • IPO Year
  • APRE 2019
  • YHC N/A
  • Fundamental
  • Price
  • APRE $1.39
  • YHC $0.85
  • Analyst Decision
  • APRE Strong Buy
  • YHC
  • Analyst Count
  • APRE 1
  • YHC 0
  • Target Price
  • APRE $20.00
  • YHC N/A
  • AVG Volume (30 Days)
  • APRE 141.8K
  • YHC 427.1K
  • Earning Date
  • APRE 11-07-2025
  • YHC 11-12-2025
  • Dividend Yield
  • APRE N/A
  • YHC N/A
  • EPS Growth
  • APRE N/A
  • YHC N/A
  • EPS
  • APRE N/A
  • YHC N/A
  • Revenue
  • APRE $841,012.00
  • YHC $2,390,517.00
  • Revenue This Year
  • APRE N/A
  • YHC $69.97
  • Revenue Next Year
  • APRE N/A
  • YHC $403.29
  • P/E Ratio
  • APRE N/A
  • YHC N/A
  • Revenue Growth
  • APRE N/A
  • YHC 31.49
  • 52 Week Low
  • APRE $1.31
  • YHC $0.68
  • 52 Week High
  • APRE $5.00
  • YHC $98.00
  • Technical
  • Relative Strength Index (RSI)
  • APRE 42.40
  • YHC 44.64
  • Support Level
  • APRE $1.31
  • YHC $0.86
  • Resistance Level
  • APRE $1.46
  • YHC $0.92
  • Average True Range (ATR)
  • APRE 0.09
  • YHC 0.07
  • MACD
  • APRE -0.01
  • YHC -0.00
  • Stochastic Oscillator
  • APRE 22.11
  • YHC 22.00

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About YHC LQR House Inc. Common Stock

LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.

Share on Social Networks: